Literature DB >> 18797643

Antiretroviral therapy and early mortality in South Africa.

Andrew Boulle1, Peter Bock, Meg Osler, Karen Cohen, Liezl Channing, Katherine Hilderbrand, Eula Mothibi, Virginia Zweigenthal, Neviline Slingers, Keith Cloete, Fareed Abdullah.   

Abstract

OBJECTIVE: To describe province-wide outcomes and temporal trends of the Western Cape Province antiretroviral treatment (ART) programme 5 years since inception, and to demonstrate the utility of the WHO monitoring system for ART.
METHODS: The treatment programme started in 2001 through innovator sites. Rapid scaling-up of ART provision began early in 2004, located predominantly in primary-care facilities. Data on patients starting ART were prospectively captured into facility-based registers, from which monthly cross-sectional activity and quarterly cohort reports were aggregated. Retention in care, mortality, loss to follow-up and laboratory outcomes were calculated at 6-monthly durations on ART.
FINDINGS: By the end of March 2006, 16 234 patients were in care. The cohort analysis included 12 587 adults and 1709 children. Women accounted for 70% of adults enrolled. After 4 and 3 years on ART respectively, 72.0% of adults (95% confidence interval, CI: 68.0-75.6) and 81.5% (95% CI: 75.7-86.1) of children remained in care. The percentage of adults starting ART with CD4 counts less than 50 cells/microl fell from 51.3% in 2001 to 21.5% in 2005, while mortality at 6 months fell from 12.7% to 6.6%, offset in part by an increase in loss to follow-up (reaching 4.7% at 6 months in 2005). Over 85% of adults tested had viral loads below 400 copies/ml at 6-monthly durations until 4 years on ART.
CONCLUSION: The location of care in primary-care sites in this programme was associated with good retention in care, while the scaling-up of ART provision was associated with reduced early mortality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18797643      PMCID: PMC2649489          DOI: 10.2471/blt.07.045294

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  16 in total

1.  Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model.

Authors:  Anthony D Harries; Patrick Gomani; Roger Teck; Olga Ascurra de Teck; Edwin Bakali; Rony Zachariah; Edwin Libamba; Andrina Mwansambo; Felix Salaniponi; Rex Mpazanje
Journal:  Trans R Soc Trop Med Hyg       Date:  2004-12       Impact factor: 2.184

2.  True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi.

Authors:  Joseph Kwong-Leung Yu; Solomon Chih-Cheng Chen; Kuo-Yang Wang; Chao-Sung Chang; Simon D Makombe; Erik J Schouten; Anthony D Harries
Journal:  Bull World Health Organ       Date:  2007-07       Impact factor: 9.408

3.  Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa.

Authors:  David Coetzee; Katherine Hilderbrand; Andrew Boulle; Beverley Draper; Fareed Abdullah; Eric Goemaere
Journal:  Bull World Health Organ       Date:  2005-07       Impact factor: 9.408

4.  Viewpoint: a pragmatic approach to constructing a minimum data set for care of patients with HIV in developing countries.

Authors:  William M Tierney; Eduard J Beck; Reed M Gardner; Beverly Musick; Mark Shields; Naomi M Shiyonga; Mark H Spohr
Journal:  J Am Med Inform Assoc       Date:  2006-02-24       Impact factor: 4.497

5.  Public health lessons from a pilot programme to reduce mother-to-child transmission of HIV-1 in Khayelitsha.

Authors:  M F Abdullah; T Young; L Bitalo; N Coetzee; J E Myers
Journal:  S Afr Med J       Date:  2001-07

6.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.

Authors:  Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

7.  Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.

Authors:  Jessica H Oyugi; Jayne Byakika-Tusiime; Kathleen Ragland; Oliver Laeyendecker; Roy Mugerwa; Cissy Kityo; Peter Mugyenyi; Thomas C Quinn; David R Bangsberg
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

8.  Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.

Authors:  Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood
Journal:  Antivir Ther       Date:  2007

9.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

Authors:  Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

Review 10.  Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox; Christopher J Gill
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  69 in total

1.  Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting.

Authors:  G U van Zyl; W Preiser; S Potschka; A T Lundershausen; R Haubrich; D Smith
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

2.  Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Authors:  Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

3.  Differences in antiretroviral scale up in three South African provinces: the role of implementation management.

Authors:  Helen Schneider; David Coetzee; Dingie Van Rensburg; Lucy Gilson
Journal:  BMC Health Serv Res       Date:  2010-07-02       Impact factor: 2.655

4.  When to start antiretroviral therapy in resource-limited settings: a human rights analysis.

Authors:  Nathan Ford; Alexandra Calmy; Samia Hurst
Journal:  BMC Int Health Hum Rights       Date:  2010-03-31

5.  Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study.

Authors:  Charlotte Schutz; Andrew Boulle; Dave Stead; Kevin Rebe; Meg Osler; Graeme Meintjes
Journal:  AIDS Res Ther       Date:  2010-05-26       Impact factor: 2.250

Review 6.  Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.

Authors:  Matthew P Fox; Sydney Rosen
Journal:  Trop Med Int Health       Date:  2010-06       Impact factor: 2.622

7.  Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces.

Authors:  Geoffrey Fatti; Ashraf Grimwood; Peter Bock
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

8.  Secular trends in pediatric antiretroviral treatment programs in rural and urban Zambia: a retrospective cohort study.

Authors:  Catherine G Sutcliffe; Carolyn Bolton-Moore; Janneke H van Dijk; Matt Cotham; Bushimbwa Tambatamba; William J Moss
Journal:  BMC Pediatr       Date:  2010-07-30       Impact factor: 2.125

9.  From HIV diagnosis to treatment: evaluation of a referral system to promote and monitor access to antiretroviral therapy in rural Tanzania.

Authors:  Ray Nsigaye; Alison Wringe; Maria Roura; Samuel Kalluvya; Mark Urassa; Joanna Busza; Basia Zaba
Journal:  J Int AIDS Soc       Date:  2009-11-11       Impact factor: 5.396

10.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

Authors:  P Mugyenyi; A S Walker; J Hakim; P Munderi; D M Gibb; C Kityo; A Reid; H Grosskurth; J H Darbyshire; F Ssali; D Bray; E Katabira; A G Babiker; C F Gilks; H Grosskurth; P Munderi; G Kabuye; D Nsibambi; R Kasirye; E Zalwango; M Nakazibwe; B Kikaire; G Nassuna; R Massa; K Fadhiru; M Namyalo; A Zalwango; L Generous; P Khauka; N Rutikarayo; W Nakahima; A Mugisha; J Todd; J Levin; S Muyingo; A Ruberantwari; P Kaleebu; D Yirrell; N Ndembi; F Lyagoba; P Hughes; M Aber; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Whitworth; K Wangati; B Amuron; D Kajungu; J Nakiyingi; W Omony; K Fadhiru; D Nsibambi; P Khauka; P Mugyenyi; C Kityo; F Ssali; D Tumukunde; T Otim; J Kabanda; H Musana; J Akao; H Kyomugisha; A Byamukama; J Sabiiti; J Komugyena; P Wavamunno; S Mukiibi; A Drasiku; R Byaruhanga; O Labeja; P Katundu; S Tugume; P Awio; A Namazzi; G T Bakeinyaga; H Katabira; D Abaine; J Tukamushaba; W Anywar; W Ojiambo; E Angweng; S Murungi; W Haguma; S Atwiine; J Kigozi; L Namale; A Mukose; G Mulindwa; D Atwiine; A Muhwezi; E Nimwesiga; G Barungi; J Takubwa; S Murungi; D Mwebesa; G Kagina; M Mulindwa; F Ahimbisibwe; P Mwesigwa; S Akuma; C Zawedde; D Nyiraguhirwa; C Tumusiime; L Bagaya; W Namara; J Kigozi; J Karungi; R Kankunda; R Enzama; A Latif; J Hakim; V Robertson; A Reid; E Chidziva; R Bulaya-Tembo; G Musoro; F Taziwa; C Chimbetete; L Chakonza; A Mawora; C Muvirimi; G Tinago; P Svovanapasis; M Simango; O Chirema; J Machingura; S Mutsai; M Phiri; T Bafana; M Chirara; L Muchabaiwa; M Muzambi; J Mutowo; T Chivhunga; E Chigwedere; M Pascoe; C Warambwa; E Zengeza; F Mapinge; S Makota; A Jamu; N Ngorima; H Chirairo; S Chitsungo; J Chimanzi; C Maweni; R Warara; M Matongo; S Mudzingwa; M Jangano; K Moyo; L Vere; N Mdege; I Machingura; E Katabira; A Ronald; A Kambungu; F Lutwama; I Mambule; A Nanfuka; J Walusimbi; E Nabankema; R Nalumenya; T Namuli; R Kulume; I Namata; L Nyachwo; A Florence; A Kusiima; E Lubwama; R Nairuba; F Oketta; E Buluma; R Waita; H Ojiambo; F Sadik; J Wanyama; P Nabongo; J Oyugi; F Sematala; A Muganzi; C Twijukye; H Byakwaga; R Ochai; D Muhweezi; A Coutinho; B Etukoit; C Gilks; K Boocock; C Puddephatt; C Grundy; J Bohannon; D Winogron; D M Gibb; A Burke; D Bray; A Babiker; A S Walker; H Wilkes; M Rauchenberger; S Sheehan; C Spencer-Drake; K Taylor; M Spyer; A Ferrier; B Naidoo; D Dunn; R Goodall; J H Darbyshire; L Peto; R Nanfuka; C Mufuka-Kapuya; P Kaleebu; D Pillay; V Robertson; D Yirrell; S Tugume; M Chirara; P Katundu; N Ndembi; F Lyagoba; D Dunn; R Goodall; A McCormick; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Kigozi; L Muchabaiwa; M Muzambi; I Weller; A Babiker; S Bahendeka; M Bassett; A Chogo Wapakhabulo; J H Darbyshire; B Gazzard; C Gilks; H Grosskurth; J Hakim; A Latif; C Mapuchere; O Mugurungi; P Mugyenyi; C Burke; S Jones; C Newland; G Pearce; S Rahim; J Rooney; M Smith; W Snowden; J-M Steens; A Breckenridge; A McLaren; C Hill; J Matenga; A Pozniak; D Serwadda; T Peto; A Palfreeman; M Borok; E Katabira
Journal:  Lancet       Date:  2009-12-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.